Don't know if this is good or bad...one thing is that there might be a little less stress on keeping on top of all the new approvals...we list the links on this site to help the process...BD
Dow Jones on Thursday examined how 2007 "is shaping up to be a slow year" for launches of new medications. FDA this year likely will approve 18 new medications, compared with 22 in 2006 and 20 in 2005. According to Dow Jones, although FDA has made no systematic changes in the review process, some observers maintain that the agency is "holding back on new drug approvals due to a greater emphasis on safety concerns" since Merck withdrew its COX-2 inhibitor Vioxx from the market in 2004 because of a link between the medication and increased risk for cardiovascular events.
Dow Jones on Thursday also examined how several small and medium-sized pharmaceutical companies "have been caught off-guard by what's seen as a tougher stance by the FDA" on approvals of new medications (Georgiades, Dow Jones, 11/1).
0 comments :
Post a Comment